



To  
The General Manager-Listing  
Corporate Relationship Department  
BSE Limited, Ground Floor,  
P.J. Towers, Dalal Street, Mumbai

28<sup>th</sup> May, 2019

Scrip Code: 524632

Dear Sir/Madam,

**SUB: - OUTCOME OF BOARD MEETING**

With reference to above subject and in compliance with Regulation 30 of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015, we hereby submit the outcome of the Meeting of the Board of Director held on today i.e. 28<sup>th</sup> May, 2019 at 01:00 p.m. and concluded on 7:00 p.m.

- 1) Considered, adopted and approved Audited Financial Results for the quarter and year ended on 31<sup>st</sup> March, 2019.
- 2) Adoption of Secretarial Audit Report for Financial Year 2018-19
- 3) The Board accepted resignation of Mr. Karnik Shah from the post of CFO of the Company.
- 4) Appointment of Mr. Karnik Shah as a CEO of the Company.
- 5) Reviewed business of the Company


Please take the same on record.

Thanking you,

Yours faithfully

For Shukra Pharmaceuticals Limited

Nileshkumar Patel  
Director  
DIN: 08316887



**CIN : L24231GJ1993PLC019079**



# SHUKRA

PHARMACEUTICALS LTD.

To  
The General Manager-Listing  
Corporate Relationship Department  
BSE Limited, Ground Floor,  
P.J. Towers, Dalal Street, Mumbai

28<sup>th</sup> May, 2019

Scrip Code: 531529

Dear Sir/Madam,

**Sub: Declaration pursuant to Regulation 33(3) (d) of the Securities Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015**

With reference to above, we hereby state that the statutory Auditor of the Company M/s B J Trivedi & Associates have issued an Audit Report with unmodified opinion on the Standalone Audited Financial Results of the Company for the quarter and year ended 31<sup>st</sup> March, 2019 in Compliance with the Regulation 33 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015.

You are requested to kindly take the same on record.

Thanking You

Yours faithfully,

For Shukra Pharmaceuticals Limited

Nileshkumar Patel  
Director  
DIN: 08316887



**CIN : L24231GJ1993PLC019079**

Regd. Office : 3rd Floor, "VEER HOUSE" Opp.WIAA Office, Judges Bungalow Road, Bodakdev, Ahmedabad-380 054.  
Factory Add.: 795, Rakanpur, Sola-Santej Road, Ta.Kalol, Dist.Gandhinagar-382721,Gujarat, India. Ph.: 02764-286317



# SHUKRA

## PHARMACEUTICALS LTD.

Standalone Statement of Profit & Loss for the quarter / twelve months ended on 31st March 2019

S/N	PARTICULARS	Standalone (Rs. Lakhs)				
		Quarter Ended			Financial Year Ended	
		31-03-2019 (Audited)	31-12-2018 (Audited)	31-03-2018 (Audited)	31-03-2019 (Audited)	31-03-2018 (Audited)
<b>1</b>	<b>Income</b>					
	Revenue from operations -					
	Other income	259.83	114.37	101.17	569.15	536.19
	<b>Total income</b>	<b>0.51</b>	<b>0.10</b>	<b>4.54</b>	<b>0.51</b>	<b>11.15</b>
<b>2</b>	<b>Expenses</b>	<b>260.34</b>	<b>114.47</b>	<b>105.71</b>	<b>569.66</b>	<b>547.34</b>
(a)	Cost of materials consumed	48.09	8.39	15.76	137.05	124.32
(b)	Purchases of stock-in-trade	-	-	-	-	-
(c)	Changes in inventories of finished goods, work-in-progress and stock-in-trade	48.75	-	-	(15.96)	-
(d)	Employee benefit expense	48.56	54.79	36.99	196.01	128.36
(e)	Finance costs	0.04	-	3.78	0.06	4.56
(f)	expense	41.00	18.42	36.20	96.26	73.70
(f)	Other Expenses	25.62	28.64	73.84	77.26	121.79
	<b>Total expenses</b>	<b>212.06</b>	<b>110.24</b>	<b>166.57</b>	<b>490.68</b>	<b>452.73</b>
<b>3</b>	<b>Total profit before exceptional items and tax</b>	<b>48.28</b>	<b>4.23</b>	<b>(60.86)</b>	<b>78.98</b>	<b>94.61</b>
4	Exceptional items	-	-	-	-	-
5	Total profit before tax	<b>48.28</b>	<b>4.23</b>	<b>(60.86)</b>	<b>78.98</b>	<b>94.61</b>
7	<b>Tax expense</b>					
8	Current tax	12.07	1.06	(20.69)	19.75	17.03
9	Deferred tax	12.96	3.10	(24.75)	12.96	(24.75)
10	Total tax expenses	<b>25.03</b>	<b>4.16</b>	<b>(15.42)</b>	<b>46.28</b>	<b>(7.72)</b>
11	Net movement in regulatory deferral account balances related to profit or loss and the					
<b>14</b>	<b>operations</b>	<b>23.25</b>	<b>0.07</b>	<b>(15.42)</b>	<b>46.28</b>	<b>102.33</b>
15	before tax					
16	Tax expense of discontinued operations					
17	after tax	<b>23.25</b>	<b>0.07</b>	<b>(15.42)</b>	<b>46.28</b>	<b>102.33</b>
18	Share of profit (loss) of associates and joint ventures accounted for using equity method					
<b>19</b>	<b>Total profit (loss) for period</b>	<b>23.25</b>	<b>0.07</b>	<b>(15.42)</b>	<b>46.28</b>	<b>102.33</b>
20	Other comprehensive income net of taxes					
<b>21</b>	<b>Total Comprehensive Income for the period</b>	<b>23.25</b>	<b>0.07</b>	<b>(15.42)</b>	<b>46.28</b>	<b>102.33</b>
<b>22</b>	<b>Total profit or loss, attributable to</b>	<b>23.25</b>	<b>0.07</b>	<b>(15.42)</b>	<b>46.28</b>	<b>102.33</b>
	Profit or loss, attributable to owners of parent controlling interests					
<b>23</b>	<b>attributable to</b>					
	Comprehensive income for the period attributable to owners of parent					
	Total comprehensive income for the period attributable to owners of parent non-					
<b>24</b>	<b>Details of equity share capital</b>					
	Paid-up equity share capital	156.57	156.57	156.57	156.57	156.57

CIN : L24231GJ1993PLC019079

Regd. Office : 3rd Floor, "VEER HOUSE" Opp. WIAA Office, Judges Bungalow Road, Bodakdev, Ahmedabad-380 054.  
 Factory Add.: 795 Rakanpur, Sola-Santej Road, Ta. Kalol, Dist. Gandhinagar-382721, Gujarat, India. Ph.: 02764-286317





# SHUKRA

PHARMACEUTICALS LTD.

	Comprehensive income for the period attributable to owners of parent					
	Total comprehensive income for the period attributable to owners of parent non-					
<b>24</b>	<b>Details of equity share capital</b>					
	Paid-up equity share capital	156.57	156.57	156.57	156.57	156.57
	Face value of equity share capital	10.00	10.00	10.00	10.00	10.00
<b>25</b>	<b>Details of debt securities</b>					
	Paid-up debt capital					
	Face value of debt securities					-
<b>26</b>	<b>Reserves excluding revaluation reserve</b>	1,434.28	1,388.07	1,285.53	1,400.47	1,344.21
<b>27</b>	<b>Earnings per share</b>	<b>1.48</b>	<b>0.00</b>	<b>(0.98)</b>	<b>2.96</b>	<b>0.65</b>
i	<b>operations</b>					
	continuing operations	1.48	0.00	-0.98	2.96	0.65
	continuing operations	1.48	0.00	-0.98	2.96	0.65
ii	<b>operations</b>					
	discontinued operations					-
	discontinued operations					-
ii	<b>Earnings per equity share</b>					
	Basic earnings (loss) per share from continuing and discontinued operations				-	-
	Diluted earnings (loss) per share from continuing and discontinued operations				-	-
<b>28</b>	<b>Debt equity ratio</b>				-	-
<b>29</b>	<b>Debt service coverage ratio</b>				-	-
<b>30</b>	<b>Interest service coverage ratio</b>				-	-
<b>31</b>	<b>Disclosure of notes on financial results</b>					

**NOTES:**

1. The above Results have been reviewed by the Audit Committee and approved by the Board of Directors of the Company at its Meeting held on 28th May 2019. The statutory auditors have carried out a limited review of the results for the quarter ended 31st March, 2019 and have expressed an unqualified audit opinion.
2. The figures for the previous period/year have been regrouped /reclassified, wherever necessary.
3. This Statement has been prepared in accordance with the Companies (Indian Accounting Standards) Rules, 2015 (Ind As), prescribed under section 133 of the Companies Act, 2013, and other recognized accounting practices and policies to the extent applicable. Beginning April 1, 2017 Company has for the first time adopted Inds As with transition date of April 1, 2016
4. The Disclosure is as per Regulation 33 of SEBI (Listing Obligations & Discloser Requirements) Regulations, 2015.
5. The Company is operating in single segment, so above results are for single segment only.

Date: 28.05.2019

Place: Ahmedabad

For and on behalf of the Board of Directors

For Shukra Pharmaceuticals Limited

*[Signature]*  
Director/Authorised Signatory

CIN : L24231GJ1993PLC019079

Regd. Office : 3rd Floor, "VEER HOUSE" Opp.WIAA Office, Judges Bunglow Road, Bodakdev, Ahmedabad-380 054.  
Factory Add.: 795, Rakanpur, Sola-Santej Road, Ta.Kalol, Dist.Gandhinagar-382721, Gujarat, India. Ph.: 02764-286317



# SHUKRA

PHARMACEUTICALS LTD.

Standalone Balance sheet as at 31st March 2019

STATEMENT OF ASSETS AND LIABILITIES		STANDALONE	
		As at 31-03-19 (Audited)	As at 31-03-18 (Audited)
<b>A</b>	<b>ASSETS</b>		
<b>1</b>	<b>NON CURRENT ASSETS</b>		
	Property, Plant & Equipments	1555.66	1411.74
	Capital work in Progress	170.91	166.17
	Financial Assets		
	Non Current Investments		
	Loans	5.17	4.72
	Deferred Tax Assets (Net)	0.00	0.00
	Other Non Current Assets	0.00	0.00
		0.00	0.00
		1731.74	1582.63
<b>2</b>	<b>Current Assets</b>		
	Inventories	27.05	14.48
	Financial Assets		
	Trade Receivables		
	Cash and Cash Equivalents	526.75	292.66
	Bank Balance	13.61	4.87
	Loans	11.32	1.52
	Current Tax Assets (Net)	525.11	492.75
	Other Current Assets		
		99.47	21.21
		1203.31	827.49
	<b>Total Assets</b>	<b>2935.05</b>	<b>2410.12</b>
<b>B</b>	<b>EQUITY AND LIABILITIES</b>		
<b>1</b>	<b>EQUITY</b>		
	Share Capital	156.57	156.57
	Other Equity	1400.47	1344.21
		1557.04	1500.78
<b>2</b>	<b>Liabilities</b>		
	<b>A - Non Current Liabilities</b>		
	Borrowings		
	Other Financial Liabilities	640.59	358.34
	Provisions	0.00	0.00
		297.47	284.51
		938.06	642.85
	<b>B - Current Liabilities</b>		
	Borrowings		
	Trade Payables	0.00	0.00
	Other Financial Liabilities	380.95	193.44
	Other Current Liabilities	0.00	0.00
	Provisions	0.00	0.00
		59.00	73.05
		439.95	266.49
	<b>Total equity and liabilities</b>	<b>2935.05</b>	<b>2410.12</b>

CIN : L24231GJ1993PLC019079

Regd. Office : 3rd Floor, "VEER HOUSE" Opp.WIAA Office, Judges Bungalow Road, Bodakdev, Ahmedabad-380 054.  
Factory Add.: 795, Rakanpur, Sola-Santej Road, Ta.Kalol, Dist.Gandhinagar-382721, Gujarat, India. Ph.: 02764-286317





**Auditor's Report on Quarterly Financial Results and year to date Results of the Company pursuant to the Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015:**

To,  
The Board of Directors,  
**Shukra Pharmaceuticals Limited**  
(Formerly known as Relish Pharmaceuticals Limited)

1. We have audited the accompanying statement of standalone financial results of **Shukra Pharmaceuticals Limited** (Formerly known as Relish Pharmaceuticals Limited) ('the company') for the quarter ended **March, 2019** and for the year then ended, attached herewith, being submitted by the company pursuant to the requirement of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, read with SEBI Circular No. CIR/CFD/FAC/62/2016 dated July 5, 2016. The quarterly standalone financial results are the derived figures between the audited figures in respect of the year ended March 31, 2019 and the published year-to-date figures up to December 31, 2018, being the date of the end of the third quarter of the current financial year, which were subjected to Limited Review. The Standalone Financial Result for the quarter ended March 31, 2019 and the Year then ended have been prepared on the basis of the standalone financial results for the nine-month period ended December 31, 2018, the audited annual standalone Ind AS financial statements as at and for the year ended March 31, 2019, and the relevant requirements of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, read with SEBI Circular No. CIR/CFD/FAC/62/2016 dated July 5, 2016, which are responsibility of the Company's Management and have been approved by the Board of Directors of the Company. Our responsibility is to express an opinion on these standalone financial results based on our review of the standalone financial results for the nine-Month period ended December 31, 2018 which were prepared in accordance with the recognition and measurement principles laid down in Indian Accounting Standard (Ind AS) 34 'Interim Financial Reporting', specified under Section 133 of the Companies Act, 2013 read with relevant rules issued there under and other accounting principles generally accepted in India; our audit of the annual standalone Ind AS financial statements as at and for the year ended March 31, 2019 and the relevant requirements of Regulation 33 of the SEBI (Listing Obligations and Disclosure



Requirements) Regulations, 2015, read with SEBI Circular No. CIR/CFD/FAC/62/2016 dated July 5, 2016.

2. We conducted our audit in accordance with auditing standards generally accepted in India. Those standards require that we plan and perform the audit to obtain reasonable assurance about whether the financial results are free of material misstatements. An audit includes examining, on a test basis, evidence supporting the amounts disclosed as financial results. An audit also includes assessing the accounting principles used and significant estimates made by management. We believe that our audit provides a reasonable basis for our opinion.
3. In our opinion and to the best of our information and according to the explanations given to us, these quarterly standalone financial results, as well as the year to date results:
  - i. Are presented in accordance with the requirements of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, read with SEBI Circular No. CIR/CFD/FAC/62/2016 dated July 5, 2016, in this regard; and
  - ii. Give a true and fair view of the total comprehensive income (comprising of net profit and other comprehensive income) and other financial information for the quarter ended March 31, 2019 and for the year then ended.
4. Further, read with paragraph 1 above, we report that the figures for the quarter ended March 31, 2019 represent the derived figures between the audited figures in respect of the financial year ended March 31, 2019 and the published year-to-date figures up to December 31, 2018, being the date of the end of the third quarter of the current financial year, as required under the Regulation and the Circular.

For, B J Trivedi & Associates,  
Chartered Accountants  
FRN 111042W

Place: Ahmedabad  
Date: 20/05/2019



  
Bharat Trivedi  
Proprietor  
M. No. 39595